The Gastroenterology Market in 2025 is driven by the rising prevalence of GI diseases and breakthrough technologies such as single-use endoscopes and AI-assisted imaging, prioritizing safer, faster, and more accurate GI care. As a result, the U.S. market is entering a new phase of innovation.
In this blog, we explore key drivers behind funding and technological adoption, market size, competitive positioning, and the outlook for providers and investors.
Want to Learn More About The Gastrointestinal Endoscopic Devices Market?
Get a complimentary report summary today:
Table of Contents
➜ What Are Gastrointestinal Disorders?
➜ How Big Is the U.S. GI Endoscopic Market??
➜ Who Leads the U.S. GI Endoscopic Market?
➜ Gastroenterology Market Emerging Technologies
↳ Why Single-Use Endoscopes Are Gaining Ground
↳ Spotlight: SpyGlass™ DS System by Boston Scientific
↳ How AI Is Boosting GI Diagnostics
➜ What’s Next for the GI Market
➜ Get a Complimentary Gastrointestinal Endoscopic Devices Market Summary
Key Takeaways
- The U.S. GI endoscopic device market reached ~$6 billion in 2023 and is projected to grow to ~$9.2 billion by 2030.
- Exact Sciences leads the diagnostics category with its Cologuard FIT-DNA test, detecting over 623,000 cancers/precancers and supporting increased screening uptake.
- Boston Scientific dominates multiple device segments, from stents and biopsy tools to single-use scopes and the SpyGlass DS platform.
- Olympus remains a key player in endoscopes and diagnostic imaging and is investing in AI innovations for better procedure planning.
- Single-use endoscopes (Boston Scientific Exalt D™, Ambu’s aScope™) help hospitals reduce infection risk and boost efficiency.
- AI-enhanced systems from Medtronic and Olympus are improving real-time polyp detection, supporting better colorectal cancer screening.
What Are Gastrointestinal Disorders?
Gastrointestinal (GI) disorders are conditions that affect the digestive system, including the stomach, intestines, liver, and other organs involved in processing food. GI disorders can affect quality of life, nutrition, and overall health.
These disorders can cause symptoms like stomach pain, bloating, diarrhea, constipation, nausea, and heartburn.
Some conditions require long-term management, while others may increase the risk of more serious diseases. Early detection and treatment help prevent complications and improve well-being.
These conditions affect millions and often require diagnosis through endoscopy, imaging, or non-invasive tests, making the GI device market critical for early detection and treatment.
How Big Is the US GI Endoscopic Market?
The U.S. GI endoscopic device market was valued at $5.9 billion in 2023 and is expected to reach approximately $9.2 billion by 2030.
This growth follows rising procedure volumes, non-invasive test adoption, and the push for better infection prevention through innovation.
Who Leads the U.S. GI Device Market?
In 2025, Exact Sciences, Boston Scientific, and Olympus lead the U.S. GI device market, each shaping innovation through advanced diagnostics and intervention tools.
Exact Sciences’ Cologuard FIT-DNA test drives early cancer detection, Boston Scientific excels in ERCP tools and stenting, and Olympus dominates GI endoscopes with AI-driven surgical planning solutions.
- Exact Sciences: Driven by its Cologuard FIT-DNA stool test (FDA-approved 2014), the company screened over 16 million people and detected more than 623,000 cancers/precancers, saving an estimated $22 billion in healthcare costs
- Boston Scientific: A leading device vendor in stents, ERCP tools, snares, and EUS needles. Their single-use duodenoscopes, cholangioscopes, and the standalone SpyGlass™ DS System drive their continued dominance.
- Olympus: Maintains leadership in GI endoscopes and accessory tools. It’s also integrating smart technologies and AI through surgical planning tools.
Gastroenterology Market Emerging Technologies
Why Single-Use Endoscopes Are Gaining Ground
Single-use endoscopes are transforming gastroenterology by addressing long-standing concerns around infection control, workflow efficiency, and reprocessing costs.
Initially propelled by the COVID-19 pandemic and rising hygiene standards, these devices have since become a go-to solution in both hospitals and outpatient centers.
These devices eliminate the need for costly and time-consuming reprocessing, while lowering cross-contamination risks, particularly critical in high-volume GI procedures.
Despite these advantages, some experts argue that environmental concerns and waste management need to be addressed as disposable devices become more widespread.
Spotlight: SpyGlass™ DS System by Boston Scientific
SpyGlass™ offers single-operator cholangioscopy with direct visualization of bile and pancreatic ducts. The SpyGlass system provides real-time, high-resolution images, helping doctors diagnose and treat conditions like bile duct stones, strictures, and tumors.
This device streamlines procedures such as:
- Targeted biopsies for suspicious lesions
- Stone fragmentation and removal in the bile ducts
- Diagnosis of cholangitis and other ductal diseases
As the incidence of pancreaticobiliary disorders rises, especially in aging populations, demand for such advanced visualization tools is expected to climb.
How AI Is Boosting GI Diagnostics
Artificial Intelligence is becoming an integral part of gastrointestinal diagnostics, particularly in colorectal cancer screening and polyp detection.
Companies like Medtronic and Olympus are leading the charge, embedding AI directly into endoscopy platforms.
Key benefits include:
- Real-time polyp detection: AI algorithms automatically flag anomalies such as adenomas and early-stage cancers during colonoscopies.
- Increased Adenoma Detection Rates (ADR): Studies have shown AI-assisted colonoscopies improve ADR, a critical metric linked to reduced colorectal cancer mortality.
- Reduced physician fatigue: By highlighting suspicious areas, AI systems lessen the cognitive load on endoscopists, especially during long or repetitive procedures.
One example is Olympus’s AI-enhanced platforms, which integrate detection and image classification features directly into their VISERA™ series systems. These tools not only improve diagnostic precision but also reduce the need for follow-up procedures caused by missed lesions.
As AI continues to mature, it’s expected to drive:
- Faster workflows
- Lower repeat procedure rates
- Better overall patient outcomes
Healthcare providers are now beginning to view AI not just as an add-on, but as a core tool in modern GI diagnostics and decision-making.
What’s Next for the GI Device Market?
Looking forward, these trends will sustain growth:
- Increased AI integration, from detection to procedure guidance.
- Higher single-use device adoption across ambulatory and hospital settings.
- Innovation in minimally invasive and tissue-applicator tools to support therapeutic endoscopy.
- Expansion of non-invasive diagnostics, including blood-and-stool tests and expanded insurance coverage, fuelled by Exact Sciences’ recent Medicare inclusion for Cologuard Plus and development of the Oncodetect MRD blood test
Get a Complimentary US Gastrointestinal Endoscopic Devices Market Report Summary
For an in-depth understanding of these trends, delve into our detailed US Gastrointestinal Endoscopic Devices Market Report. This report offers a comprehensive analysis of the US Gastrointestinal Endoscopic Devices Market, covering:
Screening & Diagnostics: FIT-DNA, GI endoscopy, capsule endoscopy, virtual colonoscopy.
Intervention & Therapy: Stenting, dilation, anti-reflux device implantation, Barrett’s esophagus ablation.
Tissue & Specimen Handling: Biopsy, polypectomy snare, specimen retrieval, foreign-body removal.
Supportive Procedures:
Or request a complimentary US Gastrointestinal Endoscopic Devices Market Summary – completely free.
